HilleVax, Inc.
HLVX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.53 | 0.10 | -0.02 | -0.00 |
| FCF Yield | -107.44% | -14.97% | -10.87% | -1.75% |
| EV / EBITDA | 0.18 | -3.67 | -5.94 | -6.13 |
| Quality | ||||
| ROIC | -86.37% | -41.89% | -34.42% | -76.87% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.70 | 0.39 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -12.08% | -42.37% | -578.05% | -694.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.84 | 1.25 | 3.73 | -0.34 |
| Interest Coverage | 46.80 | -55.75 | -19.07 | -18.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,263.11 | -768.90 | -124,586.67 |